{"id":380550,"date":"2020-11-12T20:03:14","date_gmt":"2020-11-13T01:03:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380550"},"modified":"2020-11-12T20:03:14","modified_gmt":"2020-11-13T01:03:14","slug":"realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/","title":{"rendered":"Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit"},"content":{"rendered":"

<\/p>\n

Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit<\/b><\/p>\n

Now Commercially Available, Both NextSeq 1000 and NextSeq 2000 Sequencers Include Integrated Informatics and Loss-less Compression Technology, Creating an Intuitive User Experience<\/i><\/p>\n

SAN DIEGO–(BUSINESS WIRE<\/a>)–Illumina, Inc.<\/a> (NASDAQ: ILMN) is further extending the reach of the NextSeq\u2122 2000 Sequencing System<\/a> with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1 billion reads in a single sequencing run, almost three times more than previously available on Illumina\u2019s mid-throughput NextSeq sequencing portfolio, expanding the range of applications that run on the system.\n<\/p>\n

\n\u201cThe advanced yet affordable P3 flow cell for the NextSeq 2000 gives customers more capacity to increase the depth and breadth of their projects and the ability to stretch their project budgets, yielding deeper insights,\u201d said Susan Tousi, Chief Product Officer of Illumina. \u201cWe\u2019re pleased to further instill customer confidence with the highest data quality ever achieved at commercial launch. Together with the on-instrument integration of our award-winning informatics solution and loss-less compression software, customers can extract actionable insights with a seamless user interface.\u201d\n<\/p>\n

\n\u201cAt University of Edinburgh, our genomics work includes single cell RNA sequencing projects which are often limited by cost,\u201d said Lee Murphy, Head of the Genetics Core at the Edinburgh Clinical Research Facility. \u201cWith the NextSeq 2000 and P3 kits, we are experiencing higher output enabling more complex, informative studies which increases the value of our offerings to our world class researchers.\u201d\n<\/p>\n

\n\u201cThe NextSeq 2000 has enabled us to bring sequencing in-house that we would otherwise have to outsource,\u201d said Bryan Venters, Director of Genomic Technologies at EpiCypher, an epigenetic technology company located in North Carolina. \u201cThis is critical because it gives us control over our development pipeline. With the release of the P3 cartridge, it will enable higher throughput sequencing and faster turnaround times.\u201d\n<\/p>\n

\nThe P3 flow cell is available in four configurations, including 100-, 200- and 300-cycles, delivering 110 Gb, 220 Gb, and 330 Gb per run, respectively. In response to customer feedback, Illumina is also launching a 50-cycle kit, targeting infectious disease, small RNA, and spatial transcriptomics applications. Additionally, at the outset of 2021, the NextSeq1000 and NextSeq 2000 platforms will come with a tool designed to allow easy recycling of >60% of the reagent cartridge used in each sequencing run.\n<\/p>\n

\nIllumina also announced the commercial availability of the NextSeq 1000, with an even more accessible price point for sequencing up to 400 million reads per run. Like the NextSeq 2000, the NextSeq 1000 offers onboard informatics for rapid secondary analysis and cloud-based, loss-less compression technology \u2013 the first of its kind to offer genomic compression technology built-in. The systems were designed with customers in mind, offering not only a clearer path to deep, actionable insights, but also our most intuitive user experience yet.\n<\/p>\n

\n\u201cBoth the NextSeq 1000 and NextSeq 2000 are designed to simplify workflows and empower labs of any size with the economy of scale to sequence more, more frequently,\u201d said Mark Van Oene, Chief Commercial Officer of Illumina. \u201cWith lower run costs, we\u2019re empowering our customers to more freely pursue their research ideas and drive genomics forward.\u201d\n<\/p>\n

\nThe NextSeq 1000 and NextSeq 2000<\/a>, as well as the P2 and P3 flow cells<\/a>, are now shipping.\n<\/p>\n

\nTo learn more, visit our website<\/a>.\n<\/p>\n

About Illumina<\/b><\/p>\n

\nIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com<\/a> and connect with us on Twitter<\/a>, Facebook<\/a>, LinkedIn<\/a>, Instagram<\/a>, and YouTube<\/a>.\n<\/p>\n

Use of forward-looking statements<\/b><\/p>\n

\nThis release contains forward-looking statements that involve risks and uncertainties, including the expectation for lower costs related to the storing and managing of genomic data costs. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services; (ii) our ability to deploy new products, services, and applications, and to expand the markets for our technology platforms; and (iii) the acceptance by customers of our newly launched products, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts\u2019 expectations, or to provide interim reports or updates on the progress of the current quarter.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201112005379\/en\/<\/a><\/span><\/p>\n

\nMedia:
\n
Karen Birmingham, PhD
\n
646-355-2111
\n
kbirmingham@illumina.com<\/a><\/p>\n

\nInvestors:
\n
Juliet Cunningham
\n
858-882-2171
\n
ir@illumina.com<\/a><\/p>\n

KEYWORDS:<\/b> Australia\/Oceania United States Singapore Japan North America Asia Pacific South Korea California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Software General Health Hardware Data Management Technology Medical Devices Genetics Public Relations\/Investor Relations Science Biotechnology Communications Health Other Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit Now Commercially Available, Both NextSeq 1000 and NextSeq 2000 Sequencers Include Integrated Informatics and Loss-less Compression Technology, Creating an Intuitive User Experience SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) is further extending the reach of the NextSeq\u2122 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1 billion reads in a single sequencing run, almost three times more than previously available on Illumina\u2019s mid-throughput NextSeq sequencing portfolio, expanding the range of applications that run on the system. \u201cThe advanced yet affordable P3 flow cell for the NextSeq 2000 gives customers more capacity to increase the depth … <\/p>\n

Continue reading “Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380550","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRealize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit Now Commercially Available, Both NextSeq 1000 and NextSeq 2000 Sequencers Include Integrated Informatics and Loss-less Compression Technology, Creating an Intuitive User Experience SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) is further extending the reach of the NextSeq\u2122 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1 billion reads in a single sequencing run, almost three times more than previously available on Illumina\u2019s mid-throughput NextSeq sequencing portfolio, expanding the range of applications that run on the system. \u201cThe advanced yet affordable P3 flow cell for the NextSeq 2000 gives customers more capacity to increase the depth … Continue reading "Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T01:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201112005379r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit\",\"datePublished\":\"2020-11-13T01:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\\\/\"},\"wordCount\":858,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201112005379r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\\\/\",\"name\":\"Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201112005379r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-11-13T01:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201112005379r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201112005379r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/","og_locale":"en_US","og_type":"article","og_title":"Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit - Market Newsdesk","og_description":"Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit Now Commercially Available, Both NextSeq 1000 and NextSeq 2000 Sequencers Include Integrated Informatics and Loss-less Compression Technology, Creating an Intuitive User Experience SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) is further extending the reach of the NextSeq\u2122 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1 billion reads in a single sequencing run, almost three times more than previously available on Illumina\u2019s mid-throughput NextSeq sequencing portfolio, expanding the range of applications that run on the system. \u201cThe advanced yet affordable P3 flow cell for the NextSeq 2000 gives customers more capacity to increase the depth … Continue reading \"Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T01:03:14+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201112005379r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit","datePublished":"2020-11-13T01:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/"},"wordCount":858,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201112005379r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/","name":"Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201112005379r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-11-13T01:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201112005379r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201112005379r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/realize-the-full-potential-of-the-nextseq-2000-with-the-power-of-the-p3-reagent-kit-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380550"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380550\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}